IMRX Nasdaq

Immuneering Corp Class A

IMRX | $1.77 -4.84% -5.08% 180K

(0.0% 1d) (-33.1% 1m) (-84.3% 1y) (0.0% 2d) (0.0% 3d) (-2.9% 7d) (-57.19% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 51,831,391

Sec Filling | Patents | 2021 employees

add to watch list Paper trade email alert is off

Press-releases

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -12.26% | O: 0.0% H: 4.72% C: 3.3%
cancer pancreatic

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-03 (Crawled : 20:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -22.5% | O: 2.08% H: 2.86% C: -4.08%
conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -22.18% | O: 2.09% H: 0.41% C: -0.41%
first tumors treat trial advanced

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -68.37% | O: -21.09% H: 7.96% C: -37.5%
tumors positive topline trial results

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -68.66% | O: 0.59% H: 4.02% C: -1.93%

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
Published: 2024-03-11 (Crawled : 12:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -71.65% | O: 0.61% H: 0.76% C: -10.08%
first tumors trial

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -70.0% | O: 2.1% H: 6.16% C: 1.11%
association cancer research preclinical meeting program

Immuneering to Participate in the Cowen 44th Annual Health Care Conference
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -69.76% | O: 24.88% H: 0.0% C: -19.92%
conference health care

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Published: 2024-03-01 (Crawled : 13:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -70.0% | O: -1.94% H: 4.11% C: 1.15%
business year financial results

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 180K

| -71.82% | O: 6.97% H: 2.83% C: -4.25%
fda cancer pancreatic designation

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001790340-24-000042	4	2024-03-25	2024-03-22	Buy	P	25000	111766
0001790340-24-000040	4	2024-03-25	2024-03-22	Buy	P	3900	3900